Monografie
Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): Week 28 results from the ongoing phase IIIb randomized, double‐blind, parallel‐group, GUIDE study
- Sprache
-
Englisch
- Identifier
-
1304678938
Beteiligte Personen und Organisationen
Schäkel, Knut
Reich, Kristian
Asadullah, Khusru
Pinter, Andreas
Jullien, Denis
Weisenseel, Peter
Paul, Carle F.
Gomez, Mario
Wegner, Sven
Personke, Yvonne
Kreimendahl, Fabian
Chen, Yanqing
Angsana, Julianty
Leung, Monica W. L.
Eyerich, Kilian
Reich, Kristian
Asadullah, Khusru
Pinter, Andreas
Jullien, Denis
Weisenseel, Peter
Paul, Carle F.
Gomez, Mario
Wegner, Sven
Personke, Yvonne
Kreimendahl, Fabian
Chen, Yanqing
Angsana, Julianty
Leung, Monica W. L.
Eyerich, Kilian
- DOI
-
10.1111/jdv.19236
- URN
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
07.12.2023, 15:21 MEZ
Objekttyp
- Monografie
Beteiligte
- Schäkel, Knut
- Reich, Kristian
- Asadullah, Khusru
- Pinter, Andreas
- Jullien, Denis
- Weisenseel, Peter
- Paul, Carle F.
- Gomez, Mario
- Wegner, Sven
- Personke, Yvonne
- Kreimendahl, Fabian
- Chen, Yanqing
- Angsana, Julianty
- Leung, Monica W. L.
- Eyerich, Kilian
Ähnliche Objekte (12)
IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)
Guselkumab is superior to fumaric acid esters in patients with moderate‐to‐severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active‐comparator‐controlled phase IIIb trial (POLARIS)
Iatrogenic switch from psoriasis to eczema: what does it mean and is it predictable?
Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial
Acute generalized pustular psoriasis successfully treated with the IL‐23p19 antibody risankizumab
Guselkumab is superior to fumaric acid esters in patients with moderate‐to‐severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active‐comparator‐controlled phase IIIb trial (POLARIS)
Erfolgreiche Therapie einer akuten generalisierten pustulösen Psoriasis mit dem IL‐23p19‐Antikörper Risankizumab
Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial
Predicting persistence of atopic dermatitis in children using clinical attributes and serum proteins
The impact of the cardiovascular component and somatic mutations on ageing
Psoriasis oder Ekzem? Einjährige Ergebnisse aus dem DGUV‐Forschungsprojekt FB323 mit Einsatz des Molekularen Klassifikators bei Berufsdermatosen
IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)
Guselkumab is superior to fumaric acid esters in patients with moderate‐to‐severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active‐comparator‐controlled phase IIIb trial (POLARIS)
Iatrogenic switch from psoriasis to eczema: what does it mean and is it predictable?
Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial
Acute generalized pustular psoriasis successfully treated with the IL‐23p19 antibody risankizumab
Guselkumab is superior to fumaric acid esters in patients with moderate‐to‐severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active‐comparator‐controlled phase IIIb trial (POLARIS)
Erfolgreiche Therapie einer akuten generalisierten pustulösen Psoriasis mit dem IL‐23p19‐Antikörper Risankizumab
Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial
Predicting persistence of atopic dermatitis in children using clinical attributes and serum proteins
The impact of the cardiovascular component and somatic mutations on ageing
Psoriasis oder Ekzem? Einjährige Ergebnisse aus dem DGUV‐Forschungsprojekt FB323 mit Einsatz des Molekularen Klassifikators bei Berufsdermatosen
IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)
Guselkumab is superior to fumaric acid esters in patients with moderate‐to‐severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active‐comparator‐controlled phase IIIb trial (POLARIS)
Iatrogenic switch from psoriasis to eczema: what does it mean and is it predictable?
Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial
Acute generalized pustular psoriasis successfully treated with the IL‐23p19 antibody risankizumab
Guselkumab is superior to fumaric acid esters in patients with moderate‐to‐severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active‐comparator‐controlled phase IIIb trial (POLARIS)
Erfolgreiche Therapie einer akuten generalisierten pustulösen Psoriasis mit dem IL‐23p19‐Antikörper Risankizumab
Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial
Predicting persistence of atopic dermatitis in children using clinical attributes and serum proteins
The impact of the cardiovascular component and somatic mutations on ageing